IRCT20240611062093N1招募中Unknown
Comparing the effects of bevacizumab and aflibercept in the treatment and outcome of patients with retinopathy of prematurity (ROP)
Zahedan University of Medical Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Completion of patient files
- •Patients who need treatment
- •Patients needing treatment with anti-VEGF drugs
排除标准
- •Patients with underlying disease, including congenital glaucoma, congenital cataract
- •Patients with vitreous hemorrhages
研究者
相似试验
已完成
1 期
A phase I study of bevacizumab and amrubicin after platinum-based chemotherapy in patients with advanved non-squamous non-small cell lung canceron-Small Cell Lung Cancer Non-Squamous cell lung cancerJPRN-UMIN000008182ational Hospital Organization Kyushu Medical Center Department of Respiratory Medicine15
进行中（未招募）
1 期
Assessment of the efficacy of bevacizumab in combination with Folfiri as second-line treatment after the failure of the cisplatin (or carboplatin)-etoposide combination in patients suffering from an advanced inoperable poorly differentiated neuroendocrine carcinoma of an unknown or gastroentero-pancreatic primary cancer. A phase 2 non-comparative randomized study. PRODIGE 41 - BEVANEC studyeuroendocrine carcinomaMedDRA version: 20.0Level: PTClassification code 10057270Term: Neuroendocrine carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001305-16-FRHospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation
招募中
2 期
A PhaseII Study of Bevacizumab in Combination with S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer reviously treated with platinum based chemotherapyon-Squamous Non-Small-Cell Lung CancerJPRN-UMIN000005486Hiroshima citizens hospital Department of Medical Oncology34
招募中
不适用
Phase II study of Bevacizumab in combination with Paclitaxel in metastatic breast cancer patients with asymptomatic brain metastases.Breast CancerJPRN-UMIN000010466Kansai medical university23
进行中（未招募）
不适用
Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. - Bevacizumab + Docetaxel-Capecitabina MammellaPatients with advanced breast cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2006-003929-83-ITGRUPPO ONCOLOGICO ITALIANO DI RICERCA